EuCorVac-19

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[1][2][3][4]

EuCorVac-19
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular

Clinical trials

Phase I/II

EuBiologics Co., Ltd started the study on February 23, 2021.[5] The study is called "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults"[5] As of April 26, 2021, the trial is ongoing and participants are being accepted. It has an expected primary completion date of March 2022. The study is expected to be completed in January 2023.

Phase III

EuBiologics registered a phase III trial with a starting date of October 1, 2022 in the Philippines.[6]

References
  1. "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. Retrieved 17 April 2021.
  2. Moon-hee C (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine 'EuCOVAC-19'". Business Korea. Retrieved 17 April 2021.
  3. "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. Retrieved 17 April 2021.
  4. "Firm looks to build vaccine manufacturing plant in PH". ABS-CBN News. 12 April 2021. Retrieved 17 April 2021.
  5. "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
  6. "A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults". ClinicalTrials.gov. National Institutes of Health. 27 October 2022. Retrieved 30 October 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.